Market Overview

UPDATE: Stifel Nicolaus Initiates IDEXX Laboratories at Hold on Valuation, Market Share Risk

Related IDXX
Top 4 NASDAQ Stocks In The Diagnostic Substances Industry With The Highest ROI
T. Rowe Price Reports 10.7% Stake In Idexx Labs

Stifel Nicolaus initiated coverage on IDEXX Laboratories (NASDAQ: IDXX) with a Hold rating.

Stifel Nicolaus commented, "IDEXX's dominance in what has proven to be a relatively resilient vet market is likely to continue. That said, we believe this is already reflected in the stock's premium valuation. In addition, our work uncovers some headwinds that may strengthen as we enter 2013, notably, future chemistry share losses and an unfavorable change in the distributor landscape."

IDEXX Laboratories closed at $93.89 on Wednesday.

Latest Ratings for IDXX

DateFirmActionFromTo
Oct 2014Canaccord GenuityMaintainsBuy
Oct 2014Stifel NicolausMaintainsBuy
Jun 2014Canaccord GenuityUpgradesHoldBuy

View More Analyst Ratings for IDXX
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (IDXX)

Around the Web, We're Loving...

Get Benzinga's Newsletters